Form 8-K Pacira Pharmaceuticals, For: Apr 30

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Form 8-K Pacira Pharmaceuticals, For: Apr 30

BofA/Merrill Lynch Upgrades Pacira Pharmaceuticals (PCRX) to Neutral (Earlier)

July 31, 2015 9:48 AM EDT

BofA/Merrill Lynch earlier upgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Underperform to Neutral with a price target of $69.00 (from $70.00).

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $61.80 yesterday.

... More

Pacira Pharma (PCRX) Misses Q2 EPS by 1c

July 30, 2015 8:17 AM EDT

Pacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.23, $0.01 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $59.1 million versus the consensus estimate of $62.97 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

... More